Conservative Judges Are Manipulating the History of Eugenics to Overturn Roe v. Wade
By Mark Joseph Stern,
Slate
| 04. 15. 2021
On Wednesday, the U.S. Court of Appeals for the 6th Circuit upheld an Ohio law that prohibits doctors from performing an abortion if they know the reason is because the fetus has been diagnosed with Down syndrome. The 9–7 decision seems to defy the Supreme Court’s decisions in Roe v. Wade and Planned Parenthood v. Casey, which found a constitutional right to terminate a pregnancy before viability. Yet the court’s conservative judges claimed that those precedents did not necessarily apply here, because Ohio was not simply regulating abortion; the state claimed to be combatting eugenics by protecting disabled fetuses from discrimination. The Supreme Court has never squarely confronted these “trait-selection” laws, which often forbid abortions because of race or sex as well; while these bans have cropped up around the country in recent years, courts have consistently ruled that they are foreclosed by precedent. The 6th Circuit’s conservative majority, by contrast, made a bet that today’s SCOTUS will weaken or overturn Roe and Casey to uphold Ohio’s statute—and, perhaps, overturn the constitutional right to abortion in the...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...